Related Experiment Video

Updated: May 15, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

Vlado Perkovic1, Hiddo Lambers Heerspink, John Chalmers

  • 1The George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia. vperkovic@georgeinstitute.org.au

Kidney International
|January 11, 2013
PubMed

Insights

Intensive glucose control significantly lowers the risk of major kidney outcomes in type 2 diabetes patients. This strategy reduced end-stage renal disease (ESRD) by 65% and albuminuria by up to 30%.

Area of Science:

  • Nephrology
  • Endocrinology
  • Clinical Trials

Background:

  • The impact of strict glucose management on kidney health in type 2 diabetes is not fully understood.
  • Kidney disease is a major complication of type 2 diabetes, affecting a significant portion of patients.

Purpose of the Study:

  • To evaluate the effect of an intensive glucose-lowering strategy on major kidney outcomes in type 2 diabetes.
  • To assess the impact on end-stage renal disease (ESRD), albuminuria, and creatinine levels.

Main Methods:

  • The ADVANCE trial randomized 11,140 participants to intensive (HbA1c ≤6.5%) or standard glucose control.
  • Kidney outcomes including ESRD, albuminuria, and creatinine changes were assessed over a median of 5 years.

Main Results:

  • Intensive glucose control reduced ESRD risk by 65% (20 vs. 7 events).
  • Microalbuminuria risk decreased by 9% and macroalbuminuria by 30%.
  • Albuminuria progression was reduced by 10%, and regression increased by 15%.

Conclusions:

  • Intensive glucose control markedly improves major kidney outcomes in type 2 diabetes.
  • This strategy offers significant protection against end-stage renal disease and albuminuria progression.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...